Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models

PURPOSE: Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) gefitinib have shown dramatic effects against EGFR mutant lung cancer, patients become resistant by various mechanisms, including gatekeeper EGFR-T790M mutation, MET amplification, and KRAS mutation, thereafter relapsing. AZD62...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Yiqing, Wu, Xiuxiu, Yin, Yunhong, Yang, Yan, Ma, Dedong, Li, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074836/
https://www.ncbi.nlm.nih.gov/pubmed/24939055
http://dx.doi.org/10.1186/1756-9966-33-52

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074836/
https://www.ncbi.nlm.nih.gov/pubmed/24939055
http://dx.doi.org/10.1186/1756-9966-33-52

Ejemplares similares